Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $31.83 Consensus Target Price from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average rating of “Hold” by the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $31.8333.

A number of brokerages have recently issued reports on STRO. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research note on Tuesday, January 20th. Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Wedbush reiterated a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Finally, HC Wainwright upped their price target on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research note on Monday, December 22nd.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Sutro Biopharma during the 2nd quarter worth approximately $27,000. Bridgeway Capital Management LLC increased its stake in Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares in the last quarter. Savant Capital LLC acquired a new position in Sutro Biopharma during the second quarter worth $37,000. CWM LLC raised its holdings in Sutro Biopharma by 73.2% during the second quarter. CWM LLC now owns 56,657 shares of the company’s stock worth $40,000 after purchasing an additional 23,941 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Sutro Biopharma by 174.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock worth $43,000 after purchasing an additional 38,561 shares in the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Stock Up 4.9%

NASDAQ STRO opened at $20.44 on Friday. The stock has a market capitalization of $173.94 million, a P/E ratio of -0.78 and a beta of 1.55. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $20.47. The firm has a 50-day moving average price of $14.02 and a 200 day moving average price of $10.84.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.